Fusion protein targeting CD39 and TGF beta and application thereof

CN120230222APending Publication Date: 2025-07-01GUANGDONG FAPON BIOPHARMA INC +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202311863377.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-12-29
Publication Date
2025-07-01

Smart Images

  • Figure BDA0004646307470000101
    Figure BDA0004646307470000101
  • Figure BDA0004646307470000102
    Figure BDA0004646307470000102
  • Figure BDA0004646307470000103
    Figure BDA0004646307470000103
Patent Text Reader

Abstract

The invention relates to the technical field of biology, and particularly discloses a fusion protein targeting CD39 and TGF beta and application of the fusion protein. Specifically, the present invention provides a fusion protein comprising a CD39 binding unit and a TGF [beta] inhibiting portion. The fusion protein is combined with CD39 and TGF beta at the same time, the membrane CD39 is blocked from degrading ATP, the TGF beta activity is inhibited, the function and immune activation of effector T cells are promoted, meanwhile, immunotoxicity is reduced, and tumors can be treated.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • TGF-β binding antibodies

    US7494651B2

  • Humanized anti-TGF-beta antibodies

    US8012482B2

  • Antibodies to TGFβ

    US8383780B2

  • Tgfbeta 2 antibodies

    WO2017141208A1